Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference

• Published in: Clinical infectious diseases Vol. 37; no. Supplement-3; pp. S225 - S264
• Main Authors: Stevens, David A., Moss, Richard B., Kurup, Viswanath P., Knutsen, Alan P., Greenberger, Paul, Judson, Marc A., Denning, David W., Crameri, Reto, Brody, Alan S., Light, Michael, Skov, Marianne, Maish, William, Mastella, Gianni
• Format: Journal Article
• Language: English
• Published: United States The University of Chicago Press 01-10-2003; University of Chicago Press
• Subjects: Allergens; Allergic bronchopulmonary aspergillosis; Animals; Antibodies; Antifungal Agents - therapeutic use; Antigens; Aspergillosis, Allergic Bronchopulmonary - diagnosis; Aspergillosis, Allergic Bronchopulmonary - drug therapy; Aspergillosis, Allergic Bronchopulmonary - etiology; Aspergillus; Aspergillus fumigatus; Asthma; Congresses as Topic; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - microbiology; Eosinophils; Humans; Lungs; T lymphocytes
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1086/376525

Because of the difficulties of recognizing allergic bronchopulmonary aspergillosis (ABPA) in the context of cystic fibrosis (because of overlapping clinical, radiographic, microbiologic, and immunologic features), advances in our understanding of the pathogenesis of allergic aspergillosis, new possibilities in therapy, and the need for agreed-upon definitions, an international consensus conference was convened. Areas addressed included fungal biology, immunopathogenesis, insights from animal models, diagnostic criteria, epidemiology, the use of new immunologic and genetic techniques in diagnosis, imaging modalities, pharmacology, and treatment approaches. Evidence from the existing literature was graded, and the consensus views were synthesized into this document and recirculated for affirmation. Virulence factors in Aspergillus that could aggravate these diseases, and particularly immunogenetic factors that could predispose persons to ABPA, were identified. New information has come from transgenic animals and recombinant fungal and host molecules. Diagnostic criteria that could provide a framework for monitoring were adopted, and helpful imaging features were identified. New possibilities in therapy produced plans for managing diverse clinical presentations.